FDA AD POLICY "UNDERMINES" EFFICACY STANDARD, "INHIBITS" SUPPLEMENTAL APPLICATIONS, EX-FDAer SAYS; SEPARATE STANDARD FOR AD DATA PROPOSED
This article was originally published in The Gray Sheet
Executive SummaryFDA's policy on product advertising "undermines" the efficacy standard by preventing the dissemination of "information on data quality" and forcing the creation of an "underground" system of data dissemination, former agency staffer Jur Strobos, MD, now with the D.C. firm Greenberg, Traurig, states in a policy paper to be released at the Food & Drug Law Institute's educational conference in Washington, D.C. on Dec. 12-13.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.